(MENAFN- IMARC Group)
The latest report by IMARC Group, titled“ Alopecia treatment market Report by Drug Type (Minoxidil, Finasteride, and Others), Indication (Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others), Gender (Male, Female), Route of Administration (Oral, Topical, Injectable), Distribution channel (Hospitals, Retail Pharmacies, online Pharmacies), and Region 2024-2032 “, The global alopecia treatment market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting
a growth rate (CAGR) of 4.1% during 2024-2032.
Alopecia treatment refers to the medical and therapeutic methods used to address alopecia, a condition where hair is lost from some or all body parts, primarily the scalp. The most common type is androgenic alopecia, known as male-pattern baldness and female-pattern baldness, based on the gender of the affected individual. There are various causes of alopecia, including genetics, hormonal changes, medical conditions, and medications. Treatment options vary depending on the type and cause of hair loss. The primary goal of alopecia treatment is to reduce hair loss and promote hair regrowth. Common treatments include topical solutions like minoxidil, oral medications like finasteride, and surgical procedures like hair transplantation. Other therapies may involve light therapy or corticosteroid injections. The effectiveness of each treatment can vary, and not all individuals may see regrowth. At present, alopecia treatment finds extensive applications in dermatology clinics, pharmaceutical research, and cosmetic industries across the globe.
For an in-depth analysis, you can refer sample copy of the report:
https://www.imarcgroup.com/alopecia-treatment-market/requestsample
Alopecia Treatment Market
Trends and Drivers:
The global alopecia treatment market is primarily driven by the rising incidences of alopecia and the growing image-conscious population becoming more aware of hair loss and its potential treatments. Moreover, the expanding geriatric population, often associated with an increased risk of alopecia due to aging, has augmented the demand for effective treatments, thereby fostering market growth. Apart from this, numerous technological advancements and research, including the development of innovative treatment options, with pharmaceutical companies intensifying research and development (R&D) efforts to formulate better drugs and solutions, has catalyzed market growth. Besides this, the heightening popularity of hair transplant surgeries and the introduction of novel therapies, like platelet-rich plasma (PRP) and laser treatment, is another major growth-inducing factor. Along with this, increasing investments in advertising campaigns that promote hair growth products that raises awareness and acceptance among consumers is propelling market growth. Furthermore, the escalating stress levels and changing lifestyle patterns that cause hair loss contributing to market growth.
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Drug Type:
Minoxidil Finasteride Others
Breakup by Indication:
Androgenic Alopecia Alopecia Areata Alopecia Totalis Others
Breakup by Gender:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Hospitals Retail Pharmacies Online Pharmacies
Market Breakup by Region:
North America (United States, Canada) Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa
Competitive Landscape with Key Player:
Aclaris Therapeutics Inc. Cellmid Limited Cipla Limited Dr. Reddy's Laboratories Ltd. GlaxoSmithKline plc HCell Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Taisho Pharmaceutical Holdings Co. Ltd Teva Pharmaceutical Industries Ltd
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN29012024004122016232ID1107780397
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.